These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 2902602)

  • 1. Controlled beta-receptor blockade with esmolol and flestolol.
    Murthy VS; Frishman WH
    Pharmacotherapy; 1988; 8(3):168-82. PubMed ID: 2902602
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Esmolol hydrochloride: an ultrashort-acting, beta-adrenergic blocking agent.
    Angaran DM; Schultz NJ; Tschida VH
    Clin Pharm; 1986 Apr; 5(4):288-303. PubMed ID: 2871961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Controlled beta-receptor blockade with flestolol: a novel ultrashort-acting beta-blocker.
    Murthy VS; Hwang TF; Rosen LB; Gorczynski RJ
    J Cardiovasc Pharmacol; 1987 Jan; 9(1):72-8. PubMed ID: 2434798
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Flestolol: an ultra-short-acting beta-adrenergic blocking agent.
    Barton SD; Burge J; Turlapaty P; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A36-A39. PubMed ID: 2870085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Esmolol: a titratable short-acting intravenous beta blocker for acute critical care settings.
    Turlapaty P; Laddu A; Murthy VS; Singh B; Lee R
    Am Heart J; 1987 Oct; 114(4 Pt 1):866-85. PubMed ID: 2889341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hemodynamic effects of flestolol, a titratable short-acting intravenous beta-adrenergic receptor blocker.
    Strom J; Josephson M; Frishman WH; Singh B; Heilbrunn S; Osterle S; Turlapaty P; Viray R; Coe J; Bell V
    J Clin Pharmacol; 1988 Mar; 28(3):276-82. PubMed ID: 2896204
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Esmolol--beta-adrenergic blocking agent with ultrashort action].
    Marenović T; Stojiljković MP; Marković M
    Srp Arh Celok Lek; 1992 Jun; 120 Suppl 4():65-70. PubMed ID: 18193815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Esmolol. A review of its therapeutic efficacy and pharmacokinetic characteristics.
    Wiest D
    Clin Pharmacokinet; 1995 Mar; 28(3):190-202. PubMed ID: 7758250
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Esmolol and the adrenergic response to perioperative stimuli.
    Murthy VS; Hwang TF; Sandage BW; Laddu AR
    J Clin Pharmacol; 1986 Mar; 26(S1):A27-A35. PubMed ID: 2870083
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics and pharmacodynamics of flestolol, a new short-acting, beta-adrenergic receptor antagonist.
    Achari R; Drissel D; Hulse JD; Bell V; Turlapaty P; Laddu A; Matier WL
    J Clin Pharmacol; 1987 Jan; 27(1):60-4. PubMed ID: 2890664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Basic pharmacology of esmolol.
    Gorczynski RJ
    Am J Cardiol; 1985 Oct; 56(11):3F-13F. PubMed ID: 2864846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Esmolol in anesthesiology: pharmacology and indications].
    Fita G; Gomar C; Rovira I
    Rev Esp Anestesiol Reanim; 1999 Nov; 46(9):404-14. PubMed ID: 10613078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical rationale for the use of an ultra-short acting beta-blocker: esmolol.
    Barbier GH; Shettigar UR; Appunn DO
    Int J Clin Pharmacol Ther; 1995 Apr; 33(4):212-8. PubMed ID: 7620691
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacology and pharmacokinetics of esmolol.
    Reynolds RD; Gorczynski RJ; Quon CY
    J Clin Pharmacol; 1986 Mar; 26(S1):A3-A14. PubMed ID: 2870084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Managing critically ill patients with esmolol. An ultra short-acting beta-adrenergic blocker.
    Gray RJ
    Chest; 1988 Feb; 93(2):398-403. PubMed ID: 2892647
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical pharmacokinetics and therapeutic efficacy of esmolol.
    Wiest DB; Haney JS
    Clin Pharmacokinet; 2012 Jun; 51(6):347-56. PubMed ID: 22515557
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tolerance and beta-adrenergic blocking activity of flestolol, a short-acting beta blocker.
    Turlapaty P; Burge J; Hulse J; Achari R; Bell V; Mosberg H; Laddu A
    Clin Pharmacol Ther; 1986 May; 39(5):543-9. PubMed ID: 3698462
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esmolol: a novel cardioselective, titratable, intravenous beta-blocker with ultrashort half-life.
    Covinsky JO
    Drug Intell Clin Pharm; 1987 Apr; 21(4):316-21. PubMed ID: 2882993
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacodynamics and pharmacokinetics of esmolol, a short-acting beta-blocking agent, in children.
    Cuneo BF; Zales VR; Blahunka PC; Benson DW
    Pediatr Cardiol; 1994; 15(6):296-301. PubMed ID: 7838803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of flestolol, a new ultrashort-acting beta-adrenergic blocking agent, for supraventricular tachyarrhythmias.
    Steinberg JS; Katz RJ; Somberg JC; Keefe D; Laddu AR; Burge J
    Am J Cardiol; 1986 Nov; 58(10):1005-8. PubMed ID: 2877563
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.